Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Total Liabilities (2018 - 2025)

Historic Total Liabilities for China SXT Pharmaceuticals (SXTC) over the last 8 years, with Q3 2025 value amounting to $6.1 million.

  • China SXT Pharmaceuticals' Total Liabilities fell 6166.15% to $6.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $6.1 million, marking a year-over-year decrease of 6166.15%. This contributed to the annual value of $6.2 million for FY2025, which is 3232.57% down from last year.
  • Per China SXT Pharmaceuticals' latest filing, its Total Liabilities stood at $6.1 million for Q3 2025, which was down 6166.15% from $6.2 million recorded in Q1 2025.
  • China SXT Pharmaceuticals' 5-year Total Liabilities high stood at $18.6 million for Q1 2021, and its period low was $6.1 million during Q3 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' median Total Liabilities value was $9.4 million (recorded in 2023), while the average stood at $11.4 million.
  • As far as peak fluctuations go, China SXT Pharmaceuticals' Total Liabilities surged by 6781.95% in 2024, and later plummeted by 6166.15% in 2025.
  • Over the past 5 years, China SXT Pharmaceuticals' Total Liabilities (Quarter) stood at $8.9 million in 2021, then dropped by 17.87% to $7.3 million in 2022, then surged by 30.44% to $9.5 million in 2023, then surged by 67.82% to $16.0 million in 2024, then plummeted by 61.66% to $6.1 million in 2025.
  • Its Total Liabilities stands at $6.1 million for Q3 2025, versus $6.2 million for Q1 2025 and $16.0 million for Q3 2024.